Pfizer Inc. and BioNTech SE have released new research and data that shows the COVID-19 vaccine they developed creates high immunity after only one dose and can be successfully stored in regular freezers rather than ultracold temperatures.
The Wall Street Journal reports that the findings by both companies “provide strong arguments in favor of delaying the second dose of the two-shot vaccine.” The United Kingdom is reportedly already using this strategy and giving as many citizens as possible the first dose even if that means the second dose’s administration is postponed. Almost one-third of the adult population in the U.K. has received at least the first vaccine shot.
The Wall Street Journal reports,
A single shot of the vaccine is 85% effective in preventing symptomatic disease 15 to 28 days after being administered, according to a peer-reviewed study conducted by the Israeli government-owned Sheba Medical Center and published in the Lancet medical journal. Pfizer and BioNTech recommend that